Tata Capital's TCHF II has invested up to $10 million in Apex Kidney Care for an undisclosed equity stake, with the aim of expanding the company's dialysis services nationwide.

Speaking on the partnership, Vamesh Chovatia, Partner, Tata Capital Healthcare Fund II said,

“We’re excited to partner with Apex Kidney Care, a leader in the dialysis space in the country. At TCHF II, we take a holistic approach to investing capital and backing companies like AKC that address glaring gaps in healthcare. We look forward to working closely with AKC and making high-quality and cost- effective services available to nephrology patients. We believe India needs many more Apex kind of organisations to deliver dialysis services and effectively address the healthcare need gap in the industry.”

Dr Jatin Kothari, Co-founder and Director, Apex Kidney Care said,

“Today is a milestone in the life story of Apex Kidney Care as we announce our partnership with Tata Capital Healthcare Fund II, a relationship that will strengthen our commitment to revolutionise kidney care in India. This new partnership underscores the value of our business model and our vision in delivering high quality dialysis services.

The combined strength promises to open many new avenues to advance the business, and favorably touch the lives of thousands of patients fighting kidney disease. We begin this journey with an immense sense of excitement, energy and confidence to be at the forefront in spearheading the change we want to see for all our patients.”

Indranil Roy Choudhury, CEO, Apex Kidney Care said,

“This is a defining moment for us at Apex Kidney Care and we are honoured to be associated with Tata Capital Healthcare Fund II. This association will significantly augment our servicing capabilities and will play a critical role in realising our mission of creating a kidney care ecosystem for patients – built on compassion, respect, transparency and desired treatment outcomes.

Tata Capital Healthcare Fund II’s support will help us make dialysis and allied services accessible and affordable to all. We will continue to partner with clinicians both in existing and newer geographies as we embark on our journey to significantly ramp up our existing infrastructure. Delivering the desired treatment outcomes and thus improving patient survival will continue to be our purpose.”